12-Month Data on Foslevodopa/Foscarbidopa for Parkinson’s Disease
New 12-month clinical data regarding foslevodopa/foscarbidopa continuous subcutaneous infusion reveals sustained motor symptom control and a manageable safety profile for advanced Parkinson’s disease patients. Evaluated within European and international regulatory ... Read More